Vivek Subbiah: Novel Precision Oncology Trial Designs in Early Phase Clinical trials
Vivek Subbiah shared on LinkedIn:
“The Keystone Precision Oncology, Breckenridge, Colorado meeting was incredible!
Such a great honor to be invited to Chair a session and deliver a lecture on ‘Novel Precision Oncology Trial Designs in Early Phase Clinical trials’
Attendees from academia/industry/ pharma/basic science/translational scientists/clinical trialists/ societies/ journal editors had amazing discussions.
Many of the drugs and advancements discussed with new mechanisms of action here will hit the clinic in 1-2 years.
Q and A sessions were the best part.
Great time connecting with friends and amazing colleagues! ”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023